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Abstract
Background
Few data on the virological determinants of hepatitis B virus (HBV) infection are available
from southern Africa.
Methods
We enrolled consecutive HIV-infected adult patients initiating antiretroviral therapy (ART) at
two urban clinics in Zambia and four rural clinics in Northern Mozambique between May
2013 and August 2014. HBsAg screening was performed using the Determine1 rapid test.
Quantitative real-time PCR and HBV sequencing were performed in HBsAg-positive
patients. Risk factors for HBV infection were evaluated using Chi-square and Mann-Whit-
ney tests and associations between baseline characteristics and high level HBV replication
explored in multivariable logistic regression.
Results
Seventy-eight of 1,032 participants in Mozambique (7.6%, 95% confidence interval [CI]: 6.1–
9.3) and 90 of 797 in Zambia (11.3%, 95% CI: 9.3–13.4) were HBsAg-positive. HBsAg-posi-
tive individuals were less likely to be female compared to HBsAg-negative ones (52.3% vs.
66.1%, p<0.001). Among 156 (92.9%) HBsAg-positive patients with an available measure-
ment, median HBV viral load was 13,645 IU/mL (interquartile range: 192–8,617,488 IU/mL)
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and 77 (49.4%) had high values (>20,000 UI/mL). HBsAg-positive individuals had higher lev-
els of ALT and AST compared to HBsAg-negative ones (both p<0.001). In multivariable anal-
yses, male sex (adjusted odds ratio: 2.59, 95%CI: 1.22–5.53) and CD4 cell count below
200/μl (2.58, 1.20–5.54) were associated with high HBV DNA. HBV genotypes A1 (58.8%)
and E (38.2%) were most prevalent. Four patients had probable resistance to lamivudine
and/or entecavir.
Conclusion
One half of HBsAg-positive patients demonstrated high HBV viremia, supporting the early
initiation of tenofovir-containing ART in HIV/HBV-coinfected adults.
Introduction
Chronic hepatitis B virus (HBV) infection is present in approximately 3 million HIV-infected
persons worldwide [1]. HIV/HBV-coinfected individuals are at higher risk of death and are
more likely to develop hepatic complications and to have an impaired immunological recovery
during antiretroviral therapy (ART), compared to HIV-monoinfected patients [2–4]. Although
approximately 10% of HIV-infected patients are estimated to be HBsAg-positive in sub-Saha-
ran Africa (SSA) [5], only few studies have assessed the level of HBV replication and drug resis-
tance in this part of the world.
HBV viral load is a strong predictor of the risk of developing hepatocellular carcinoma and
plays an important role in treatment success. Time to HBV suppression under tenofovir (TDF)
is delayed with increasing baseline HBV DNA and the risk of persistent viral replication after
two years of therapy is highest with an elevated pre-ART HBV viral load [6, 7]. In one of few
published reports on HBV outcomes following TDF-containing ART in SSA, pre-therapy
HBV-DNA was the only factor independently associated with sub-optimal HBV response [8].
In that study, which included 55 HIV/HBV-coinfected individuals from Zambia, HBV geno-
type A1 predominated (76%) and only 2 patients had drug-resistance mutations in the HBV
polymerase. Although several small studies from other countries in southern Africa have
reported HBV sequencing data among ART-naïve HIV/HBV-coinfected populations [9–11],
no large study has been conducted in Mozambique and Zambia to evaluate the HBV genotype
distribution and drug resistance mutations.
We assessed the prevalence of HBV infection in HIV-infected individuals from an interna-
tional collaboration including ART programs in Mozambique and Zambia, and performed a
detailed analysis of demographic, clinical and virological characteristics associated with high
pre-ART HBV DNA. We also studied the distribution of HBV genotypes and the prevalence of
pre-ART HBV drug resistance mutations to add to the scarce data from Southern Africa [9,
12].
Materials and Methods
Study population
Consecutive HIV-infected adults initiating ART at two urban clinics in Lusaka, Zambia, and
four rural clinics in Cabo Delgado, Northern Mozambique were enrolled between May 2013
and August 2014. They were classified as HIV/HBV-coinfected if HBsAg-positive. Routine
pre-ART assessment consisted of a physical examination and measurements of CD4 cells, liver
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transaminases, creatinine and full blood count according to national recommendations. All
data were entered into an electronic database, using the protocol of the International epidemio-
logical Databases to Evaluate AIDS in Southern Africa (IeDEA-SA) [13]. Written informed
consent was obtained from all patients. Ethics approval was obtained from the Biomedical
Research Ethics Committee of the University of Zambia School of Medicine, the Institutional
Review Board of University of North Carolina at Chapel Hill, USA, and from the Comité
Nacional de Bioética para a Saúde, República de Moçambique.
Laboratory analyses
HBsAg was assessed using the Determine1 (Alere, Yavne, Israel) rapid test on whole blood
using finger prick sampling. To determine HBV DNA levels, quantitative real-time polymerase
chain reaction (PCR) was performed on plasma samples from Zambian participants and on
dried blood spots (DBS) fromMozambican participants using the COBAS Ampliprep/TaqMan
System (Roche diagnostics, Indianapolis, USA). We recently showed that the use of DBS to
measure HBV DNA level in southern Africa was feasible and reliable [14]. As in our Zambian
laboratory DNA measurements from paired plasma samples were in average 1.59 log higher
than those from DBS, we converted DNA values from DBS to generate estimated plasma values
using a multiplication factor of 39. DNA extraction and amplification procedures used for DBS
are explained in detail elsewhere [14]. An in-house protocol was used for HBV sequencing:
HBV DNA was extracted using the QIAamp DNA mini kit (Qiagen, Hilden, Germany), a pri-
mary PCR covering the codons 18 to 330 of the RT-domain of the Pol gene was conducted
using publically available primers [15] and, if necessary, a nested PCR (codons 83–288) was
performed using published primers [16]. DNA was purified using QIAquick PCR purification
kit (Qiagen, Hilden, Germany). Sanger sequencing was performed using an AB3130 genetic
analyzer (Life Technologies, California, USA) and nucleotide sequences analyzed with
Sequencher version 5.0 (Gene Codes Corporation, Michigan, USA). Geno2Pheno (www.
geno2pheno.org) was used to predict HBV genotypes and drug resistances. HBeAg serology
was only available from participants in Zambia. Laboratory analyses were performed at the
Centre for Infectious Disease Research in Zambia Central Laboratory and at the Institute for
Infectious Diseases, University of Bern.
Statistical analyses
HBV prevalence estimates were calculated with 95% confidence intervals (CI). Factors associ-
ated with HBsAg-positivity were evaluated using Chi-square and Mann-Whitney tests. Associ-
ations between demographic, clinical and virological characteristics with the presence of high
HBV viral load (20,000 IU/mL [17]) were evaluated using the Chi-square test. An AST-to-
platelet-ratio-index (APRI) score>1.5 was used to define significant liver fibrosis [18, 19]. Fac-
tors associated with high HBV DNA level were further explored in multivariable logistic
regression analyses adjusted for sex, age, stage of HIV disease and CD4 cell counts. All statisti-
cal analyses were performed using Stata software version 13.1 (College Station, Texas, USA).
Results
Demographic and clinical characteristics
Seventy-eight of 1,032 participants in Mozambique (7.6%, 95% confidence interval [CI]: 6.1–
9.3) and 90 of 797 in Zambia (11.3%, 95% CI: 9.3–13.4) were HBsAg-positive. HBsAg-positive
individuals were less likely to be female compared to those who tested HBsAg-negative (52.3%
vs.66.1%, p<0.001) but age, WHO stage, BMI, CD4, haemoglobin and platelets were similar in
HIV/HBV-Coinfection in Southern Africa
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both groups (Table 1). The results were consistent when comparisons were stratified by coun-
try. Median ALT and AST levels were slightly higher in HBsAg-positive patients compared to
negative ones.
HBV replication at ART initiation
Among HBsAg-positive patients, 156 (92.9%) had an available pre-ART HBV DNAmeasure-
ment (Fig 1). Median DNA level was 13,645 IU/mL (interquartile range [IQR]: 192–8,617,488).
Overall, 26 (16.7%) had an undetectable viral load (<20 IU/mL) and 77 (49.4%) had high values
(>20,000 IU/mL). Men were more likely to have high HBV DNA than women (p = 0.01),
whereas the proportion of patients with high DNA was highest in patients with advanced WHO
stage of HIV disease (p = 0.02) and low CD4 cell counts (p = 0.001, Fig 2). Age and HBV geno-
type were not associated with the presence of a high HBV DNA level. Of 72 patients with avail-
able HBeAg serology, 33.3% had a positive result. All HBeAg+ participants had an HBV
DNA>20,000 IU/mL, whereas a high HBV DNA level was only present in 12.8% of HBeAg-
individuals (p<0.001, Fig 2). In multivariable analyses, male sex (adjusted odd ratio [aOR]:
2.59, 95% CI: 1.22–5.53) and CD4 cell count below 200/μl (aOR: 2.58, 95% CI: 1.20–5.54)
remained associated with having a high pre-ART HBV viral load.
Median transaminase levels were higher in participants with high HBV DNA compared to
those with low levels: median ALT: 38 IU/mL (IQR: 19–64) in high HBV DNA vs. 18 (12–24)
in low DNA (p<0.001), median AST: 45 IU/mL (32–71) in high HBV DNA and 29 (22–51)
in low DNA (p<0.001). Among individuals with high DNA levels, 8 (13.8%) had an APRI
Table 1. Baseline characteristics, by HBsAg-positivity status.
HBsAg-positive HBsAg-negative P-value
N = 168 N = 1,661
General characteristics
Female (%) 88 (52.3) 1,098 (66.1) <0.001
Median age in years (IQR) 33 (27–39) 32 (26–40) 0.59
WHO stage III/IV (%) 69 (41.3) 625 (37.9) 0.39
Median BMI (IQR) 20 (18–22) 20 (18–23) 0.72
Median first CD4 count in cells/μl (IQR) 229 (116–385) 255 (135–266) 0.71
Median haemoglobin in g/L (IQR) 11.3 (9.4–13.1) 11.1 (9.6–12.7) 0.80
Median platelets x109/L (IQR) 239 (185–301) 244 (189–316) 0.29
Median ALT* in IU/mL (IQR) 24 (15–44) 21 (14–34) 0.10
Median AST* in IU/mL (IQR) 38 (26–60) 32 (25–45) 0.01
HBV characteristics
Genotype, n = 102 NA
A1 (%) 60 (58.8)
E (%) 39 (38.2)
A1 and E (%) 1 (1.0)
A2 (%) 2 (2.0)
Median viral load in IU/mL (IQR) 13645 (192–8617488) NA
Viral load>20,000 IU/mL (%) 77 (49.4) NA
HBeAg-positivity (%)** 24 (33.3) NA
*only available for 66% of the study population
**only available in Zambia (n = 72)
NA: not applicable
doi:10.1371/journal.pone.0152043.t001
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score>1.5, whereas this was only the case for 4 (6.7%) patients with low HBV DNA levels
(p = 0.20).
Drug resistance
Among 102 patients with available HBV sequencing results, 58.8% had genotype A1, 38.2%
genotype E, one patient had a dual A1/E infection and two had genotype A2 (Table 1). In
Mozambique, the prevalence of genotype A1 was higher than in Zambia (72.1% vs. 49.2%).
There was no difference in the proportion of HBeAg-positive patients by genotype in Zambia
(43.5% in genotype A1 and 60.9% in genotype E, p = 0.24). Three patients showed evidence of
Fig 1. Flow chart of patients included in virological analyses. (HBV: hepatitis B virus; VL: viral load)
doi:10.1371/journal.pone.0152043.g001
HIV/HBV-Coinfection in Southern Africa
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Fig 2. Proportion of patients with high HBV viral load (>20,000 IU/mL), by sex (Panel A), age (B), WHO stage (C), CD4 cell count (D), HBV genotype
(E) and HBeAg-positivity (F).
doi:10.1371/journal.pone.0152043.g002
HIV/HBV-Coinfection in Southern Africa
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lamivudine (3TC)-resistances, three had potential resistance to entecavir (ETV) and five had
3TC or ETV compensatory mutations (Table 2). Three participants had HBV viruses with
potentially limited susceptibility to TDF.
Discussion
In this cohort of HIV-infected individuals starting ART in two distinct settings in southern
Africa, HBV prevalence was 8% in rural Mozambique and 11% in urban Zambia. Approxi-
mately one half of HBV-coinfected patients had an HBV DNA level20,000 IU/mL, with male
sex, low CD4 cell counts and HBeAg-positivity being the most important risk factors for hav-
ing a high viral load. Patients with high HBV DNA levels had higher transaminase levels and
were more likely to have significant liver fibrosis thank those with low HBV DNA.
According to a recent meta-analysis, the prevalence of HBsAg-positivity among HIV-
infected populations in southern Africa is estimated to reach 5.4% [20]. However, this study
considered a large number of reports which were not generalizable to the general population
and included only one study from Zambia and none from Mozambique. The higher estimates
found in our study were based on the findings of the systematic HBsAg-screening in two large
cohorts of general HIV outpatient care. They are comparable to previous findings from an out-
patient cohort (9% of HBsAg-positivity in HIV-infected individuals) and inpatient study
(10%) in Zambia as well as to the results of a blood donor study in urban Mozambique (10%)
[8, 21, 22]. One small study of blood donor candidates from Tete Province in rural Mozam-
bique found an even higher prevalence of HBV-infection among HIV-positive individuals.
(14%) [23]. Large prevalence studies are needed from other regions in Mozambique and Zam-
bia to better characterize local epidemiological patterns for HBV infection.
Table 2. Baseline HBV drug resistancemutations,
Patient Country Viral load (IU/ml) Genotype Resistance mutations Drug affected
Drug resistance or limited susceptibility
1 Mozambique 390 A1 N236T TDFl, ADVr
2 Mozambique 1,170 A2 L180M, S202G, M204V 3TCr, ETVr, LdTr
3 Mozambique 2,223 E N236T TDFl, ADVr
4 Mozambique 23,646,012 A1 A194T* TDFl
5 Mozambique 549,900,000 A1 M250I* ETVp
6 Zambia 100,094,677 A1 L180LM, M204MV 3TCr, ETVl, LdTr
7 Zambia >170,000,000 E V173L, L180M 3TCc,l, ETVc
Compensatory mutations only
8 Mozambique 21,489 A1 I169L ETVc
9 Mozambique 2,160,561 A1 I169L ETVc
10 Mozambique 43,001,868 A1 M250V ETVc
11 Mozambique 225,233,385 A1 V173L 3TCc
12 Zambia 377,982 A1 V173LV 3TCc
TDF: tenofovir, ETV: entecavir, 3TC: lamivudine, ADV: adefovir, LdT: telbivudine
p possible resistance,
l limited susceptibility,
c compensatory mutation,
r resistance
*Only according to the Stanford Database for HBV Drug Resistance
doi:10.1371/journal.pone.0152043.t002
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Most studies which assessed HBV replication in patients starting ART in SSA reported high
proportions (>50%) of HIV/HBV-coinfected patients with low HBV DNA levels [24–26]. In
our study, one half of HIV/HBV-coinfected patients had a viral load20,000 IU/mL. We found
that all HBeAg-positive Zambian patients had a high DNA levels, whereas the majority of
HBeAg-negative individuals had a low DNA levels, a known association also recently reported
in Malawi [9]. Thus, in settings with limited access to HBV DNA assays, HBeAg testing could
be a valuable tool to identify HBV-infected patients at high risk of liver disease. However, these
results need to be confirmed in other clinical settings as other studies from sub-Saharan Africa
reported lower correlation between HBeAg-positivity and level of HBV replication.
Like other studies in Southern Africa, we found a high prevalence of HBV genotype A1 [8,
9]. However, over one-third of HBsAg-positive patients were infected with genotype E, which
contrasted with the 1% reported in Malawi [9]. Recent studies have shown very low propor-
tions of relevant HBV drug resistance mutations in ART-naïve individuals in Malawi and Zam-
bia [8, 9], whereas 10% of patients had significant drug resistance mutations in an earlier
report from South Africa [11]. In our study, 7% (7/102) of patients had potential resistance
mutations to 3TC, ETV or TDF, which would most likely not affect treatment outcomes if
patients were prescribed TDF. The rtA194T HBV polymerase mutation, recently described in
TDF-treated HIV/HBV-coinfected patients in Spain and present in one of our participant
fromMozambique was shown to confer no or only partial resistance to TDF in vitro [27–29].
Furthermore, the mutation N236T was associated with reduced activity of TDF in vitro but
these data were never confirmed in clinical samples [30]. However, the presence of entecavir-
related mutations, present in two patients fromMozambique and one from Zambia, might be
important if access to this drug improves in the future, especially for patients with TDF-related
nephropathy [31].
Our study contributes detailed virological and clinical data from a large sample of HIV/
HBV-coinfected patients starting ART in Mozambique and Zambia, two countries with very
limited data available to date. However, our results were limited by missing data on HBeAg
in patients fromMozambique and on non-invasive liver fibrosis scores in both countries.
Although there were no major differences in clinical characteristics between patients with and
without measurements, care must be taken when interpreting data relating to these parameters.
Our findings underline the importance of universal HBV testing for HIV-infected populations
and early ART including TDF in HIV/HBV-coinfected patients as the level of HBV replication
is increased in patients with low cellular immunity and is associated with liver inflammation
and fibrosis. With TDF becoming increasingly available for HIV-infected individuals through-
out SSA, more data on the main determinants of HBV-infection are needed to inform treat-
ment guidelines.
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